Quince Therapeutics, Inc. filed an amendment to their 8-K report on May 18, 2026, correcting previously reported efficacy metrics of -35.3% and -28.1% for LAM-001 Phase 2a PH, which were incorrectly stated as 35.3% and 28.1%. This filing is significant for investors as it updates critical efficacy data.